-
Aceclofenac is now contraindicated in patients with certain established cardiovascular diseases.
-
We have simplified our medicine and device incident report systems by bringing them all under the Yellow Card Scheme.
-
New advice to minimise risk
-
Warn patients and family, monitor patients for signs of depression
-
To be used only in patients with acute blood loss and when crystalloids alone are not sufficient.
-
Do not use in closed body cavities or on deep or large wounds.
-
Reports of reconstituted solution leaking from some models of extension sets and pumps.
-
A European review identified baseline markers as predictive factors for morbidity requiring hospitalisation and mortality in cirrhotic patients.
-
Reminder to test liver function before and during treatment.
-
Available evidence shows that the risk of blood vessel blockage with ponatinib is likely to be dose-dependent, however the data are insufficient to recommend reducing the ponatinib dose.
-
We are changing our arrangements for sending out email alerts about Drug Safety Update.
-
A European review has considered MHRA evidence together with additional information from spontaneous reporting and published literature.
-
We have received reports of Colobreathe (colistimethate sodium) capsules shattering when pierced by their inhaler device.
-
Take care to tell people receiving blister packs containing a desiccant that the desiccant should not be swallowed.
-
The new offence introduced in July does not apply in Northern Ireland nor replace any existing offences of driving.
-
From October 2014 Dexamethasone 4 mg/ml injection (Organon Laboratories Limited) will be replaced by Dexamethasone 3.8 mg/ml solution for injection (Aspen Pharma Trading Limited).
-
Basiliximab (Simulect) is indicated for preventing acute organ rejection only for allogeneic renal transplantation in patients receiving organ transplantation for the first time.
-
There have been reports of thrombotic microangiopathy and nephrotic syndrome linked to interferon beta treatment.
-
Minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia.
-
New recommendations are being introduced to minimise the risk of serious hypersensitivity reactions with ferumoxytol.
-
People now need to have a medical assessment before taking domperidone to determine if it is suitable for them due to the risk of cardiac side effects.
-
We are no longer requesting all suspected adverse drug reactions (ADRs) to be reported for children.
-
Serious and fatal infusion reactions have occurred with ofatumumab and other anti-CD20 monoclonal antibodies. We remind you to always give premedication before each ofatumumab infusion. If a severe reaction occurs, interrupt…
-
Emergency contraceptives remain suitable for all women regardless of the woman’s weight or body mass index (BMI).
-
The Department for Transport has introduced a new offence of driving with certain controlled drugs above specified limits in the blood; this is likely to come into force on 2 March 2015.
-
We remind you to provide clear information to patients and caregivers regarding risk of accidental patch transfer and ingestion of patches, and need for appropriate disposal of patches.
-
Use a filter needle when drawing up reconstituted dantrolene solution.
-
Emerging clinical trial evidence of increased cardiovascular risk.
-
New warnings due to risk of hyperkalaemia, hypotension, and impaired renal function have been agreed following an EU-wide review.
-
Test liver function before and during treatment and tell patients to avoid sunlight exposure.
-
Taking zolpidem is associated with a risk of impaired driving ability the next day.
-
Statins (HMG-CoA reductase inhibitors) are widely used medicines for patients with lipid disorders and in the primary and secondary prevention of heart attack and stroke.
-
After every use, an ambulance should be called even if symptoms are improving, the individual should lie down with legs raised and, if at all possible, should not be left alone.
-
Indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use.
-
Reporting suspected adverse reactions experienced by the woman or child associated with medicines taken during pregnancy.
-
Risk of tuberculosis - screen all patients before starting treatment and monitor them closely.
-
Non-hormonal or progestogen-only contraception should be considered in some situations.
-
Restricted use and new monitoring requirements.
-
St John’s wort interacts with hormonal contraceptives reducing the effectiveness and increasing the risk of unplanned pregnancy.
-
Restricted indication and new monitoring requirements.
-
Initiate orlistat treatment only after careful consideration of the possible impact on efficacy of antiretroviral HIV medicines.
-
Old pipette design withdrawn after reported eye injuries.
-
importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
-
If thin, translucent or white-to-yellow proteinaceous strands (1–2 mm in length) are visible, filtration is advised.
-
A review of the latest evidence on the risk of thromboembolism advises to consider risk factors and remain vigilant for signs and symptoms.
- the risk of blood clots with all low-dose CHCs is small
- there is good evid…
-
Liver function should be tested before and during treatment with temozolomide.
-
Patients with active infection with this virus should not be treated with ofatumumab.
-
Severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported during treatment with capecitabine.
-
New clinical trial information is available on the timing of the loading dose of prasugrel when used in patients with unstable angina or non-ST segment elevation myocardial infarction.
-
Screening for hepatitis B virus is now recommended in all patients (not only those at risk of this infection) before starting treatment for all indications.